With a growing number of therapies under development for rare diseases, ICON’s Dr William Maier discusses how real-world evidence (RWE) can be effectively used as a historical control (HC), overcoming challenges presented in clinical development.
Rare disease drug development poses unique challenges that can be overcome by using real-world evidence (RWE). Small populations, paediatric patients, and the desire from patients and their caregivers to receive active therapy can make the conduct of randomised trials with placebo control untenable.
As an alternative, regulatory agencies have allowed the use of RWE to estimate a historical control (HC) compared to patients enrolled in an uncontrolled study. Additionally, healthcare payers understand that HCs can provide value by describing potential treatment benefit relative to untreated patients in their populations. This article will explore the advantages of using HCs, as well as several considerations for their effective use, including scientific methodology and regulatory guidance.
Benefits of historical controls
HCs can offer several advantages over concurrently collected control groups. For example, they can be created from multiple sources of disease natural history information. Disease natural history describes the demographic, genetic, environmental and other variables (eg, treatment modalities, concomitant medications) that relate to the disease’s development and outcomes over its course. Natural history information also describes the current standard of care or emergent care, which may alter disease morbidity and mortality.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
Potential sources include ongoing prospective studies such as patient registries, retrospective data from medical charts, control populations from previous trials and expert opinion. There are several rare disease resources which identify ongoing registries and patient communities with medical history information that can be useful as an HC population. These organisations include: Orphanet,1 a rare disease community resource base with information on over 6,000 rare diseases; EURODIS,2 a non-profit alliance of 869 rare disease patient organisations from 71 countries; and NORD,3 a patient advocacy organisation representing patient advocacy groups for over 280 different diseases. This variety of possible sources provides many avenues to find the best source of the requisite information for a given study.
Another benefit is that fewer patients are required in clinical trials using HCs, thereby reducing time to trial completion and speeding drug approval. However, the HC group needs to be very similar to the treated group in all respects, including outcome assessment, disease severity, duration of illness, prior treatments, and other aspects of the current standard of care that could affect the measurement and timing of treatment outcomes. To address these limitations, researchers may use selection techniques that consider independent risk factors that may bias the assessment of the key treatment outcomes, in order to match control subjects to the patients enrolled in the active treatment arm.
HC information can also be used to describe the potential benefit of innovations in treatment over time.4 For example, the Early Pseudomonal Infection Control randomised trial described the efficacy of different antibiotic regimens for eradication of newly identified Pseudomonas (Pa) in children with cystic fibrosis (CF). Provision of therapy in the trial was based on culture positivity independent of symptoms. An analysis using HCs was conducted to determine if clinical trial results were different from what would have been observed with a historical standard of care driven more heavily by respiratory symptoms. HCs were identified from the Epidemiologic Study of CF from 1995 to 1998, before widespread availability of tobramycin inhalation solution as standard of care treatment. The trial based antimicrobial therapy for newly acquired Pa resulted in a lower rate of Pa recurrence over a 15-month time period, but comparable hospitalisation rates relative to the HC. This analysis provides an example of how RWE (in the form of a patient registry) can provide evidence to describe the generalisability of trial results within a rare disease population.
Scientific methodology
Two different methodologies are used in the application of HC information in clinical development. The first, Bayesian statistical methodology, uses estimates from historical data to generate a prior probability distribution representing expected event rates for the outcome of interest in a trial, which is combined with the observed data from the clinical trial to update the estimate. Known as the posterior distribution, the estimate is essentially a weighted average of the prior and the observed data from the clinical study. The application of Bayesian methodology has been recognised by the US Food and Drug Administration (FDA) as useful in early phase clinical trials involving paediatric populations.5 Applications include more realistic estimates of adverse event rates in small populations; drawing statistical strength from adult data to make decisions about device performance in paediatrics; and shortening trials through use of adaptive designs and predictive probability of trial success before all patients finish the trial.
International regulatory agencies have normally favoured direct comparison of patient level data rather than estimated rate approaches when an HC is completely substituted for a concurrent control arm”
The second methodology, frequentist methodology, involves the direct comparison of patient-level information from historical data to patients in the clinical study. This provides an approach using similar statistical methods to those used in a randomised clinical trial. The lack of randomisation is likely to introduce bias due to differences between the historical and trial population, but several strategies may help to reduce these differences, including restriction of the patient population entering the HC; matching of the HC to increase similarity with patients in the active arm; and statistical methods to adjust for observed differences. Propensity scores,6 which are the probability of treatment assignment conditional on observed baseline characteristics, have been used to adjust for multiple patient factors in non-randomised studies. The propensity score allows for the design and analysis of a non-randomised study so that two or more groups of patients with similar characteristics are compared in the assessment of treatment effect.
The decision to take a Bayesian or frequentist approach to using historical information is generally influenced by the availability of subject-level information to compare with the active trial arm and the preference of regulatory agencies in a specific disease area or application. International regulatory agencies have normally favoured direct comparison of patient level data rather than estimated rate approaches when an HC is completely substituted for a concurrent control arm in a Phase III or registration study.
Regulatory and payer guidance
Regulatory agencies in the US and Europe have been exploring the use of disease natural history information in drug development and the FDA recently published draft guidance in which they outlined the different sources and applications of natural history information, including identification of patient populations, trial planning and the use of HC information to establish drug safety and efficacy.7 The European Medicines Agency (EMA) has also published their own guidance for the use of historical controls as part of its guidance on the conduct of trials for small populations.8
Healthcare payers also use clinical trial evidence to assess the effectiveness of treatments in making reimbursement decisions. These assessments often need to involve comparisons against multiple alternative therapies that would be impractical in the context of a clinical drug development. The use of HCs can provide a comparative population not studied in the clinical trials. Some formal health technology assessment (HTA) guidance on the use of external controls (Ecs) and RWE is available from the UK’s National Institute for Health and Care Excellence (NICE).9,10
Patel et al.11 have recently conducted an analysis of international HTA submissions from 2011-2019 to determine the acceptability of single arm clinical studies and ECs as part of the drug reimbursement process. The authors identified 433 assessments done in 21 countries that involved the use of single arm trials (five percent of the total). Overall, 52 percent of these submissions contained some type of supplementary dataset that can be designated as HCs. Based on information available, HCs were most often from prior clinical trials (24 percent), then real-world data (RWD; 20 percent), or both (eight percent). Submissions which contained ECs based on RWD had the most positive recommendations (59 percent), followed by submissions with prior trial ECs (49 percent). This suggests the widespread incorporation and acceptability of HCs in drug reimbursement decisions.
RWE from rare diseases is available from a wide variety of sources for use as an HC in rare disease drug development. HCs are used in drug approvals, HTAs and in describing the impact of new therapies in different clinical settings for rare diseases. As a result, the utility of HCs based on RWE should be evaluated for potential applications to increase speed of product approval, reimbursement and clinical practice adoption.
About the author
William Maier, MD, PhD is Chief Scientific Officer & Head, Rare Disease Research, Commercialisation and Outcomes Services, ICON. Dr Maier has over 25 years of experience in drug development and commercialisation at pharmaceutical companies in Europe, Canada, the United States and Asia. At ICON he works with pharmaceutical companies throughout the world to provide regulatory, strategic and scientific guidance on medical treatment development and commercialisation. He is a member of the EMEA’s European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (www.encepp.eu). In addition, he is a frequent speaker at medical conferences, has had academic appointments in the UK (Dundee) and the USA (North Carolina) and is a member of the Royal Society of Medicine in the UK.
Mayer-Hamblett N, Rosenfeld M, Treggiari MM et al. Standard Care versus Protocol Based Therapy for New Onset Pseudomonas aeruginosa in Cystic Fibrosis. Pediatr Pulmonol. 2013 Oct; 48(10): 943–953. Published online 2013 Jul 2. doi: 1002/ppul.22693
Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011 May; 46(3): 399–424. doi: 1080/00273171.2011.568786
Patel D, Grimson F, Mihaylova E, et al. Use of external comparators for health technology assessment submissions based on single-arm trials. Value in Health. 2021Jun8;24(8):1118–25.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.